Global Viral Vector Manufacturing Market Research Report: Forecast (2024-2030)

Market Definition

Viral vectors are specialized tools used in genetic engineering and gene therapy. They are modified viruses designed to deliver genetic material, such as therapeutic genes or DNA constructs, into target cells. By leveraging the natural ability of viruses to infect cells and introduce their genetic material, viral vectors enable scientists to manipulate gene expression, correct genetic defects, or trigger desired cellular responses for therapeutic purposes.

Market Insights & Analysis: Global Viral Vector Manufacturing Market (2024-30):

The Global Viral Vector Manufacturing Market is estimated to grow at a CAGR of around 19.22% during the forecast period, i.e., 2024-30. This growth trajectory is primarily attributed to two key factors, i.e., the escalating incidence of epidemics and pandemics, which has expedited vaccine development efforts, and the mounting investments in gene therapy initiatives. Hence, as investments in vaccine and gene therapy development improved, the demand for viral vector manufacturing services also escalated, as they have been an important part of research procedures.

Further, the prevalence of various cancer types, including blood & bladder cancer, has surged worldwide. Data from the Global Cancer Observatory 2024 reveals a notable increase in new cases of Non-Hodgkin lymphoma globally, from 44,352 cases in 2020 to 553 thousand cases in 2022. Similarly, there has been a rise in leukemia cases from 474 thousand in 2020 to 487 thousand in 2022 worldwide. Bladder cancer cases have also surged, with the number of new cases reaching 614 thousand in 2022, compared to 573 thousand in 2020.

Moreover, the escalating patient count for blood and bladder cancer globally has fueled demand for better cancer treatments. Hence, owing to this, there has been a substantial inclination of healthcare professionals toward the promising potential of cancer gene therapy and cell therapy treatments to enhance the efficacy of current therapeutic regimens. Consequently, with the growing demand for gene and cell therapy, there would be a heightened demand for viral vectors, an essential component in cancer gene therapy and cell therapy, further driving the Global Viral Vector Manufacturing Market during 2024-30.

Global Viral Vector Manufacturing Market Driver:

Increased Burden of Genetic Disorders – During the past few years, there has been a significant surge in the number of genetic disorders globally. Among them, there has been a significant rise in the number of patients with hemophilia. For instance, the World Federation of Hemophilia (WFH) reported a global count of approximately 257,146 individuals diagnosed with the condition in 2022. Specifically, hemophilia A and B cases were recorded at 208,957 and 42,203, respectively. This surge in instances of hemophilia has resulted in an amplified demand for gene therapy for treatment purposes. Thus, this demand has consequently driven the need for viral vectors, essential for delivering gene therapy, thereby accelerating growth in the Viral Vector Manufacturing Market.

Additionally, the rising prevalence of other genetic blood disorders, notably sickle-cell disease and thalassemia, has further fueled market growth. According to the World Health Organization (WHO), approximately 5% of the global population carries trait genes for hemoglobin disorders, predominantly sickle-cell disease and thalassemia. Furthermore, increasing awareness and initiatives by government and non-governmental organizations aimed at educating the public about these genetic disorders and facilitating their diagnosis and treatment are contributing to the increased number of diagnosed patients who require therapies. 

Global Viral Vector Manufacturing Market Opportunity:

Increasing Number of Clinical Trials for Gene Therapy Utilizing Viral Vectors – The increasing prevalence of genetic disorders and cancer has spurred a rise in clinical trials for novel gene therapies, consequently driving the demand for viral vectors. This expansion of clinical trials across the globe indicates the escalating investment of research organizations in gene therapy development. Thus, this would help in burgeoning the demand for viral vectors on a global scale, which would be used during the clinical trials. Furthermore, as more gene therapies enter clinical trials with the potential to address debilitating rare diseases, the demand for viral vectors is expected to increase significantly and is going to boost the Global Viral Vector Manufacturing Market.

Global Viral Vector Manufacturing Market Challenge:

Challenges Associated with Manufacturing of Viral Vectors – The challenges associated with scaling up viral vector production have been placing significant strain on viral vector manufacturing companies. These challenges span across various fronts, including manufacturing techniques, cost efficiency, safety, and regulatory compliance. The complexity of the manufacturing process demands flexibility beyond conventional methods, particularly when transitioning from laboratory-scale to large-scale production while adhering to Good Manufacturing Practices (GMP) and regulatory standards like those set by the FDA.

Handling viral vectors safely has already been complicated at smaller scales, and scaling up has been exacerbating these challenges for companies. These challenges have not only been creating operational bottlenecks but also largely affected the revenue generation of companies involved in viral vector manufacturing, thus hampering the growth of the overall market. Hence, addressing these challenges is imperative for companies to meet the increasing demand for gene therapies and to maintain competitiveness in the market.

Global Viral Vector Manufacturing Market Trend:

Rising Demand for Treatment Therapies Fueling Companies to Emphasis on Scaling Viral Vector Production Capacities – The rise in demand for viral vectors, driven by the increasing development of gene therapies, cell therapies, vaccines, and other therapeutic modalities, underscored a significant shift in the Viral Vector Manufacturing Market.  To address this growing demand for viral vectors, companies have been actively taking steps to increase their production capabilities in recent years. For instance,

• In June 2023, SK Pharmteco completed its second bioproduction facility and doubled its manufacturing footprint to 10,000m², one of the largest in Europe.

Moreover, the decision of companies like ReiThera and SK Pharmteco to expand their viral vector manufacturing capabilities reflects a recognition of the substantial market demand for viral vectors. Hence, to cater to the rising demand for viral vectors in research procedures and therapy development, the expansion of manufacturing facilities has been a significant market trend in recent years. Further, as the field of gene therapy and other advanced therapeutics continues to advance, the need for efficient and scalable viral vector production becomes increasingly evident and is likely to propel the market of viral vector manufacturing in the coming years as well.

Global Viral Vector Manufacturing Market (2024-30): Segmentation Analysis

The Global Viral Vector Manufacturing Market study by MarkNtel Advisors evaluates & highlights the major trends & influencing factors in each segment & includes predictions for the period 2024–2030 at the regional level. In accordance to the analysis, the market has been further classified as:

Based on Vector Type:

• Adenoviral Vector
• Adeno-Associated Viral Vector
• Lentiviral Vector
• Herpes Simplex Viral-Vector
• Retroviral Vector
• Others

The Adenoviral Vector segment held a major share of the Viral Vector Manufacturing Market. The efficacy, safety, and scalability of adenoviral vectors positioned them as preferred platforms for gene therapy, vaccine development, and other therapeutic applications. Further, a rise in the number of patients with genetic disorders like hemophilia, thalassemia, etc., has accelerated the demand for gene therapies. Following that, the need for adenoviral vectors that are effective vehicles for gene therapy due to their high efficiency has increased.

Based on Application:

• Gene Therapy
• Cell Therapy
• Vaccines
• Replicating Viral Vector Vaccines
• Non-Replicating Viral Vector Vaccines

Gene Therapy accounted for the largest share of the Viral Vector Manufacturing Market. This has been primarily driven by its immense potential to tackle genetic disorders, such as hemophilia and thalassemia, whose prevalence has been increasing globally. Moreover, in the face of the escalating burden of cancer and the shortcomings of conventional treatment methods, gene therapy emerged as a promising solution. Also, the clinical success and therapeutic promise exhibited by gene therapy fuel the demand for essential viral vectors like adeno-associated viruses (AAV) and lentiviruses, thus propelling the market growth.

Additionally, with a growing number of gene therapy candidates advancing through preclinical and clinical stages, the need for scalable and reliable viral vector manufacturing processes becomes increasingly pronounced. As a result, the gene therapy application segment is expected to register growth in the upcoming years as well.

Based on Region:

• North America
• South America
• Europe
• The Middle East & Rest of Africa
• Asia-Pacific

North America accounted for the largest share of the Global Viral Vector Manufacturing Market. The dominance has been attributed to the increasing number of individuals with genetic disorders, the presence of key players, and others. The regions host a large number of patients with genetic disorders. For instance, the WFH stated that in 2022, about 97,932 individuals were expected to be suffering from Hemophilia in the American region. Hence, the data reveals the higher prevalence and genetic landscape of hemophilia among other genetic disorders in the region, highlighting the need to address the complex genetic disorder effectively in the form of gene therapies, ultimately escalating the demand for viral vectors.

Global Viral Vector Manufacturing Industry Recent Development:

• 2022: Kite received the US Food and Drug Administration (FDA) approval of a viral vector manufacturing facility in Southern California to produce a commercial product.  

Gain a Competitive Edge with Our Global Viral Vector Manufacturing Market Report

• The Global Viral Vector Manufacturing Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics & make informed decisions.
• This report also highlights current market trends & future projections, allowing businesses to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
• The Global Viral Vector Manufacturing Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.